LungVax

The aim of this study is to evaluate whether administration of ChAdOx2 LungVax is safe and effective at preventing or delaying the onset of cancer in people at risk of recurrent or new NSCLC.

Lung cancer is the UK’s third most common cancer and is diagnosed in 48,500 people every year. It is highly lethal, on average only 18% of those diagnosed with lung cancer are alive at 5 years, and around 55% die within 1 year of diagnosis. This corresponds to over 35,000 deaths from lung cancer every year in the UK.

The current standard of care treatment for stage IA/B NSCLC is primary surgery followed by surveillance imaging (excluding patients eligible for neo/adjuvant therapies). Of patients with stage I disease undergoing surgical resection alone, recurrence or new primary cancers occur in 20-30% within the first 2 years.  This represents a post-operative window for a preventive intervention, such as a vaccine designed to prevent a new independent primary lung cancer or other primary cancer, or to prevent the relapse of previous stage 1 disease.

 We will use a vaccine targeting specific cancer mutations to activate a robust T cell response to recognise and kill cancer cells bearing these selected mutations.

40 participants in total will be enrolled in the first two cohorts of Module 1 (20 in Cohort 1A and 20 in Cohort 1B).

LungVax is not yet recruiting participants, we anticipate the trial will open in summer 2026.